VYNE Therapeutics (NASDAQ:VYNE) Shares Down 1.6% – What’s Next?

VYNE Therapeutics Inc. (NASDAQ:VYNE)’s stock price dropped 1.6% during mid-day trading on Friday . The company traded as low as $0.3750 and last traded at $0.37. Approximately 371,540 shares changed hands during trading, a decline of 70% from the average daily volume of 1,247,457 shares. The stock had previously closed at $0.3760.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $4.50.

VYNE Therapeutics Stock Down 1.6%

The company has a market cap of $12.32 million, a PE ratio of -0.47 and a beta of 1.95. The firm’s 50-day moving average is $0.36 and its 200-day moving average is $0.67.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.13 million. As a group, equities research analysts anticipate that VYNE Therapeutics Inc. will post -0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Exome Asset Management LLC raised its position in shares of VYNE Therapeutics by 30.9% in the 1st quarter. Exome Asset Management LLC now owns 462,801 shares of the company’s stock worth $731,000 after purchasing an additional 109,367 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in VYNE Therapeutics during the 1st quarter valued at about $111,000. DAFNA Capital Management LLC bought a new stake in VYNE Therapeutics during the 1st quarter valued at about $1,005,000. Adage Capital Partners GP L.L.C. raised its holdings in VYNE Therapeutics by 123.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 344,134 shares of the company’s stock worth $544,000 after buying an additional 190,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in VYNE Therapeutics by 42.5% in the first quarter. Parkman Healthcare Partners LLC now owns 217,978 shares of the company’s stock worth $344,000 after buying an additional 65,005 shares during the last quarter. 83.78% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.